Dr. Katherine Chang, MD

Dr. Chang practices at Fred Hutchinson Cancer Center in Seattle, Washington, part of Fred Hutchinson Cancer Center.

Dr. Chang's NPI, 1427289982, was assigned on July 31, 2009. Dr. Chang holds Washington license MD61291763.

Dr. Chang's primary practice is Fred Hutchinson Cancer Center, at 825 Eastlake Avenue East, Seattle, WA 98109.

Dr. Chang's primary practice is Fred Hutchinson Cancer Center in Seattle, Washington, part of Fred Hutchinson Cancer Center. Dr. Chang is also affiliated with EvergreenHealth Medical Center. The medical group on file is UW Physicians. Dmand AI also links Dr. Chang to 1 more hospital and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chang practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Chang's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Chang's licenses on file in 2 states: Washington and Minnesota.

CMS data shows 579 Medicare services from Dr. Chang across 6 procedure codes in 2024, for 144 Medicare patients. Medicare paid $38,969 for them. Every service was in an office.

CMS counts 144 Medicare patients who saw Dr. Chang in 2024. The largest group is 65 to 74, with 59 patients. 75% of them have high cholesterol, and 68% have high blood pressure. 9% are also on Medicaid. Their average risk score is 1.56, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Chang's median patient age at 64, with 65% women.

In 2024, Dr. Chang wrote 480 Medicare Part D claims for 97 patients. 78% of them were for generic drugs. CMS names the drug for 273 of them, across 13 drugs with 11 or more claims each, at $593,899 in total drug cost. In 2023, CMS named 123 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Chang for performance year 2024, reported through an alternative payment model (APM). Dr. Chang accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Chang as offering telehealth.

Dmand AI links 5 papers to Dr. Chang, published from 2016 to 2019. The most frequent topics are Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal and Chemotherapy, Adjuvant. Dr. Chang's most frequent co-authors are Ariella Maia Altman, MD, Jason William Denbo, MD and Eric Hans Jensen, MD.

CMS Open Payments shows 14 general payments to Dr. Chang from 4 drug and device companies from 2016 to 2024. Food and beverage make up the largest share, 92% of the total. Sanofi Pasteur Inc. paid the most, $126.